| scholarly article | Q13442814 |
| P50 | author | Ramón Cacabelos | Q66809646 |
| Rocio Martinez-Bouza | Q121434345 | ||
| P2860 | cites work | Association study of the vesicular monoamine transporter 1 (VMAT1) gene with schizophrenia in a Japanese population | Q21203891 |
| Reelin secreted by GABAergic neurons regulates glutamate receptor homeostasis | Q21562423 | ||
| The dopamine hypothesis of schizophrenia: version III--the final common pathway | Q22242827 | ||
| Rare chromosomal deletions and duplications increase risk of schizophrenia | Q22337245 | ||
| TRIM32 is an E3 ubiquitin ligase for dysbindin | Q24313358 | ||
| CNTNAP2 and NRXN1 are mutated in autosomal-recessive Pitt-Hopkins-like mental retardation and determine the level of a common synaptic protein in Drosophila | Q24315560 | ||
| Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis | Q24600775 | ||
| Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry | Q24601233 | ||
| Replication of association between working memory and Reelin, a potential modifier gene in schizophrenia | Q24606481 | ||
| Common variants conferring risk of schizophrenia | Q24614376 | ||
| The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia | Q24619976 | ||
| Sex-specific association of the Reelin gene with bipolar disorder | Q24631860 | ||
| Functional genomics in postmortem human brain: abnormalities in a DISC1 molecular pathway in schizophrenia | Q24635628 | ||
| Fine mapping on chromosome 10q22-q23 implicates Neuregulin 3 in schizophrenia | Q24643955 | ||
| Variations in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) are associated with bipolar i disorder | Q24645725 | ||
| Large recurrent microdeletions associated with schizophrenia | Q24654741 | ||
| The neurodevelopmental hypothesis of schizophrenia, revisited | Q24658343 | ||
| Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications | Q24682168 | ||
| CYP2C9 allelic variants: ethnic distribution and functional significance | Q28212029 | ||
| Reelin haploinsufficiency reduces the density of PV+ neurons in circumscribed regions of the striatum and selectively alters striatal-based behaviors | Q28237853 | ||
| Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia | Q28239401 | ||
| Association of the gene encoding neurogranin with schizophrenia in males | Q28276741 | ||
| Chronic psychotropic drug treatment causes differential expression of Reelin signaling system in frontal cortex of rats | Q28580216 | ||
| DISC1, PDE4B, and NDE1 at the centrosome and synapse | Q28585118 | ||
| Meta-analysis of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1. | Q29417150 | ||
| Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle | Q30662478 | ||
| Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms | Q43250021 | ||
| Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches | Q43256604 | ||
| Schizophrenia: the "BLOC" may be in the endosomes | Q43258034 | ||
| Influence of serotonin (5-HT) 2A-receptor and transporter (5HTT) gene polymorphism upon the effect of olanzapine | Q43274702 | ||
| Concomitant antipsychotic prescribing in US outpatient settings. | Q43280353 | ||
| Evidence of association of serotonin transporter gene polymorphisms with schizophrenia in a South Indian population | Q43284473 | ||
| Dysbindin gene (DTNBP1) and schizophrenia in Korean population | Q43826187 | ||
| CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study | Q44256339 | ||
| The biological basis of anger: associations with the gene coding for DARPP-32 (PPP1R1B) and with amygdala volume. | Q44451118 | ||
| Allelic heterogeneity in genetic association meta-analysis: an application to DTNBP1 and schizophrenia | Q44952517 | ||
| Association between genetic polymorphism of XRCC1 Arg194Trp and risk of schizophrenia. | Q45920079 | ||
| The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia. | Q45923960 | ||
| Association of plasma homocysteine and methylenetetrahydrofolate reductase C677T gene variant with schizophrenia: A Chinese Han population-based case-control study. | Q45947624 | ||
| Differential expression of glutamate transporter genes after chronic oral treatment with aripiprazole in rats. | Q45970112 | ||
| Decreased expression of Fyn protein and disbalanced alternative splicing patterns in platelets from patients with schizophrenia. | Q45980108 | ||
| FYN kinase gene: another glutamatergic gene associated with bipolar disorder? | Q45997375 | ||
| Genetic association of BDNF val66met and GSK-3beta-50T/C polymorphisms with tardive dyskinesia. | Q46003753 | ||
| Mutation screening of the glutamate cysteine ligase modifier (GCLM) gene in patients with schizophrenia. | Q46004788 | ||
| A comparative proteomics analysis of rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications. | Q46012495 | ||
| Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. | Q46013609 | ||
| Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex. | Q46033459 | ||
| Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia. | Q46039809 | ||
| HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients. | Q46040000 | ||
| Association study of PDE4B gene variants in Scandinavian schizophrenia and bipolar disorder multicenter case-control samples | Q46058975 | ||
| Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors | Q46080345 | ||
| Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. | Q46086323 | ||
| Association study of the G72 gene with schizophrenia in a Japanese population: a multicenter study | Q46112227 | ||
| Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia | Q46121813 | ||
| Genetic susceptibility to schizophrenia: role of dopaminergic pathway gene polymorphisms | Q46126668 | ||
| Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. | Q46133529 | ||
| Antipsychotic and antidepressant co-treatment: effects on transcripts of inducible postsynaptic density genes possibly implicated in behavioural disorders | Q46135298 | ||
| Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine | Q46164331 | ||
| HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study | Q46164343 | ||
| Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia. | Q46176279 | ||
| Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling | Q46182373 | ||
| Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. | Q47986721 | ||
| Gender differences in schizophrenia | Q48020725 | ||
| Brain-derived neurotrophic factor Val66Met polymorphism: association with psychopathological symptoms of schizophrenia? | Q48024613 | ||
| Genetic association and post-mortem brain mRNA analysis of DISC1 and related genes in schizophrenia | Q48506149 | ||
| TATA box-binding protein gene is associated with risk for schizophrenia, age at onset and prefrontal function | Q48545410 | ||
| Changes in alternative brain-derived neurotrophic factor transcript expression in the developing human prefrontal cortex | Q48576041 | ||
| A family-based study of the IL3RA gene on susceptibility to schizophrenia in a Chinese Han population | Q48707465 | ||
| Elevated delta-6 desaturase (FADS2) expression in the postmortem prefrontal cortex of schizophrenic patients: relationship with fatty acid composition | Q48766110 | ||
| Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication. | Q51662922 | ||
| DNA methyltransferase 3B gene increases risk of early onset schizophrenia | Q51866642 | ||
| Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: national estimates and associated factors | Q51901734 | ||
| Case-control study of association between the functional candidate gene ERBB3 and schizophrenia in Caucasian population | Q51920723 | ||
| Evidence for transmission disequilibrium at the DAOA gene locus in a schizophrenia family sample. | Q54475660 | ||
| Association of the dystrobrevin binding protein 1 gene (DTNBP1) in a bipolar case-control study (BACCS) | Q57428791 | ||
| Mutation screening of theDTNBP1exonic sequence in 669 schizophrenics and 710 controls using high-resolution melting analysis | Q58462510 | ||
| Support for NRG1 as a Susceptibility Factor for Schizophrenia in a Northern Swedish Isolated Population | Q59698060 | ||
| G72/G30(DAOA) and juvenile-onset mood disorders | Q61570663 | ||
| Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population | Q73731439 | ||
| Association study between the cholecystokinin A receptor gene and schizophrenia in the Japanese population | Q80109313 | ||
| Pharmacogenomics in Alzheimer's disease | Q80966591 | ||
| Pharmacogenomic protocols in CNS disorders and dementia | Q83106914 | ||
| Association between golli-MBP and schizophrenia in the Jewish Ashkenazi population: are regulatory regions involved? | Q83205540 | ||
| [Association analysis of neuregulin 1 gene polymorphism with schizophrenia in Chinese Han population] | Q83309364 | ||
| Association analyses of the interaction between the ADSS and ATM genes with schizophrenia in a Chinese population | Q30856619 | ||
| Persistence criteria for susceptibility genes for schizophrenia: a discussion from an evolutionary viewpoint | Q30884325 | ||
| The patterns of natural variation in human genes | Q33222347 | ||
| Analysis of flavin-containing monooxygenase 3 genotype data in populations administered the anti-schizophrenia agent olanzapine | Q33428292 | ||
| BDNF is not associated with schizophrenia: data from a Japanese population study and meta-analysis | Q33437356 | ||
| Psychotropic drugs up-regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells | Q33498169 | ||
| Apoptotic engulfment pathway and schizophrenia | Q33498943 | ||
| Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects | Q33503890 | ||
| Replication of association between schizophrenia and ZNF804A in the Irish Case-Control Study of Schizophrenia sample | Q33554950 | ||
| Familial aggregation of clinical and neurocognitive features in sibling pairs with and without schizophrenia | Q33619294 | ||
| Genetic modifiers of abnormal organelle biogenesis in a Drosophila model of BLOC-1 deficiency. | Q33630685 | ||
| A large replication study and meta-analysis in European samples provides further support for association of AHI1 markers with schizophrenia | Q33727503 | ||
| Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder | Q33793694 | ||
| The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation | Q33802672 | ||
| DNA methyltransferase 1 regulates reelin mRNA expression in mouse primary cortical cultures | Q33820124 | ||
| Pharmacogenetics of psychotropic drug response | Q33977981 | ||
| A hotspot of inactivation: The A22S and V108M polymorphisms individually destabilize the active site structure of catechol O-methyltransferase | Q34005767 | ||
| Variable number of tandem repeat polymorphisms of DRD4: re-evaluation of selection hypothesis and analysis of association with schizophrenia | Q34161627 | ||
| PM frequencies of major CYPs in Asians and Caucasians | Q34228441 | ||
| G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis | Q34508029 | ||
| Reelin down-regulation in mice and psychosis endophenotypes | Q34537189 | ||
| An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes. | Q34541215 | ||
| Cytochrome P450 polymorphisms and response to antipsychotic therapy. | Q34612118 | ||
| Reduced occipital and prefrontal brain volumes in dysbindin-associated schizophrenia | Q34660717 | ||
| Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects | Q34713638 | ||
| Association between polymorphisms in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) on chromosome 8p and schizophrenia | Q34775416 | ||
| Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study | Q34923924 | ||
| Evidence of epistasis between the catechol-O-methyltransferase and aldehyde dehydrogenase 3B1 genes in paranoid schizophrenia | Q34926937 | ||
| Association of MCTP2 gene variants with schizophrenia in three independent samples of Scandinavian origin (SCOPE). | Q34946927 | ||
| Neural mechanisms of a genome-wide supported psychosis variant | Q34978645 | ||
| Pharmacogenomics for the treatment of dementia | Q35009345 | ||
| Brain cannabinoid CB2 receptor in schizophrenia | Q35014134 | ||
| A cytogenetic abnormality and rare coding variants identify ABCA13 as a candidate gene in schizophrenia, bipolar disorder, and depression | Q35014891 | ||
| Neocortical RELN promoter methylation increases significantly after puberty | Q35015542 | ||
| Clinical proteomics: present and future prospects. | Q35053674 | ||
| The application of functional genomics to Alzheimer's disease | Q35207554 | ||
| Pharmacogenetics and drug development: the path to safer and more effective drugs | Q35889605 | ||
| Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. | Q35925154 | ||
| Pharmacogenomics and therapeutic prospects in Alzheimer's disease | Q36273420 | ||
| Structural variation of the human genome | Q36509260 | ||
| The neurobiology of cognition in schizophrenia. | Q36590627 | ||
| Molecular genetics of bipolar disorder and depression. | Q36713347 | ||
| Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research | Q36840610 | ||
| Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia | Q36886717 | ||
| Molecular mechanism of schizophrenia with reference to disrupted-in-schizophrenia 1 (DISC1). | Q36896721 | ||
| Pharmacogenetics and schizophrenia | Q36919294 | ||
| Disrupted in schizophrenia 1 and phosphodiesterase 4B: towards an understanding of psychiatric illness | Q36933003 | ||
| Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics | Q36946132 | ||
| Genomics and the future of pharmacotherapy in psychiatry | Q36951758 | ||
| Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes | Q37149314 | ||
| Association between genes of Disrupted in schizophrenia 1 (DISC1) interactors and schizophrenia supports the role of the DISC1 pathway in the etiology of major mental illnesses | Q37226971 | ||
| Transcriptional interaction of an estrogen receptor splice variant and ErbB4 suggests convergence in gene susceptibility pathways in schizophrenia | Q37254085 | ||
| Epistasis between the DAT 3' UTR VNTR and the COMT Val158Met SNP on cortical function in healthy subjects and patients with schizophrenia | Q37304041 | ||
| The future (or lack of future) of personalized prescription in psychiatry. | Q37321466 | ||
| A 2-base pair deletion polymorphism in the partial duplication of the alpha7 nicotinic acetylcholine gene (CHRFAM7A) on chromosome 15q14 is associated with schizophrenia | Q37354799 | ||
| Association of the 5'-upstream regulatory region of the alpha7 nicotinic acetylcholine receptor subunit gene (CHRNA7) with schizophrenia | Q37356715 | ||
| A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia | Q37372778 | ||
| Oestrogen--a new treatment approach for schizophrenia? | Q37394122 | ||
| Positive and negative symptoms in schizophrenia: the NMDA receptor hypofunction hypothesis, neuregulin/ErbB4 and synapse regression | Q37560810 | ||
| Family-based association of YWHAH in psychotic bipolar disorder | Q37570066 | ||
| Pharmacogenomics and therapeutic strategies for dementia | Q37592250 | ||
| The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation | Q37661688 | ||
| Transporter associated with antigen processing and the chaperone tapasin: are non-classical HLA genes keys to the pathogenesis of schizophrenia? | Q37855507 | ||
| Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia | Q38380457 | ||
| Involvement of SMARCA2/BRM in the SWI/SNF chromatin-remodeling complex in schizophrenia | Q39861509 | ||
| Differential effects of aripiprazole and haloperidol on BDNF-mediated signal changes in SH-SY5Y cells | Q39886992 | ||
| A two-method meta-analysis of Neuregulin 1(NRG1) association and heterogeneity in schizophrenia | Q39988164 | ||
| Molecular genetics of Alzheimer's disease and aging | Q40351678 | ||
| Upregulation of NRG-1 and VAMP-1 in human brain aggregates exposed to clozapine | Q42580467 | ||
| Dopaminergic pathway gene polymorphisms and genetic susceptibility to schizophrenia among north Indians. | Q43218140 | ||
| P433 | issue | 5 | |
| P921 | main subject | schizophrenia | Q41112 |
| genomics | Q222046 | ||
| pharmacogenomics | Q1152227 | ||
| P1104 | number of pages | 25 | |
| P304 | page(s) | 541-565 | |
| P577 | publication date | 2010-08-16 | |
| P1433 | published in | CNS Neuroscience & Therapeutics | Q5013184 |
| P1476 | title | Genomics and pharmacogenomics of schizophrenia | |
| P478 | volume | 17 |
| Q37930029 | Epidemiology and Risk Factors for (Tardive) Dyskinesia |
| Q92986591 | Epigenetic aging is accelerated in alcohol use disorder and regulated by genetic variation in APOL2 |
| Q85263415 | Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics |
| Q42107408 | Expression of D-Amino Acid Oxidase (DAO/DAAO) and D-Amino Acid Oxidase Activator (DAOA/G72) during Development and Aging in the Human Post-mortem Brain. |
| Q33581609 | Genetic Markers of Human Evolution Are Enriched in Schizophrenia |
| Q38003392 | Pharmacogenetics: a reality or misplaced optimism? |
| Q58781437 | Usefulness of Pharmacogenetic Analysis in Psychiatric Clinical Practice: A Case Report |
Search more.